MVAX is AVAX’s post-surgical autologous cell vaccine for Stage 4 melanoma. To date, over 600 patients have been treated with MVAX on an outpatient basis. MVAX has a Phase 3-Registration trial approved by the US FDA for the treatment of Stage 4 melanoma patients with measurable metastasis. MVAX for the adjuvant treatment of Stage 3 melanoma patients, has been discussed with the US FDA.